The relationship between prostate volume and prostate-specific antigen variability

Data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program

John H. Nichols, Stacy Loeb, E. Metter, Luigi Ferrucci, H. Ballentine Carter

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

OBJECTIVE: • To clarify the relationship between serial prostate-specific antigen (PSA) variability and prostate volume in both cancer-free participants from the Baltimore Longitudinal Study of Aging (BLSA) and patients with low-risk prostate cancer from the Johns Hopkins Active Surveillance Program (AS). MATERIALS AND METHODS: • In all, 287 men from the BLSA and 131 patients from the AS were included in the analysis, all with at least two PSA measurements and concurrent prostate volume measurements. • PSA variability was calculated in ng/mL per year, and a linear mixed-effects model was used to determine the relative effects of prostate volume, baseline PSA and age on PSA change over time. RESULTS: • In a model with prostate volume, age and baseline PSA, there was no significant relationship between prostate volume and PSA variability (BLSA, P = 0.57; AS, P = 0.49). • Only baseline PSA showed a significant relationship to PSA yearly variability (PSAYV) (P < 0.001). Specifically, a one unit higher baseline PSA (ng/mL) corresponded on average to 0.09 and 0.06 ng/mL per year higher PSAYV in the BLSA and AS populations, respectively. CONCLUSIONS: • The results of the present study suggest that the primary driver of PSA variability is the baseline PSA level, rather than prostate volume. • Clinicians might consider the baseline PSA level to help predict the expected variability in serial PSA measurements.

Original languageEnglish (US)
Pages (from-to)1304-1308
Number of pages5
JournalBJU International
Volume109
Issue number9
DOIs
StatePublished - May 1 2012

Fingerprint

Baltimore
Prostate-Specific Antigen
Longitudinal Studies
Prostate
Population Surveillance
Population Control

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

The relationship between prostate volume and prostate-specific antigen variability : Data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program. / Nichols, John H.; Loeb, Stacy; Metter, E.; Ferrucci, Luigi; Carter, H. Ballentine.

In: BJU International, Vol. 109, No. 9, 01.05.2012, p. 1304-1308.

Research output: Contribution to journalArticle

@article{d3174559856e450d98283c4d8161f7cc,
title = "The relationship between prostate volume and prostate-specific antigen variability: Data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program",
abstract = "OBJECTIVE: • To clarify the relationship between serial prostate-specific antigen (PSA) variability and prostate volume in both cancer-free participants from the Baltimore Longitudinal Study of Aging (BLSA) and patients with low-risk prostate cancer from the Johns Hopkins Active Surveillance Program (AS). MATERIALS AND METHODS: • In all, 287 men from the BLSA and 131 patients from the AS were included in the analysis, all with at least two PSA measurements and concurrent prostate volume measurements. • PSA variability was calculated in ng/mL per year, and a linear mixed-effects model was used to determine the relative effects of prostate volume, baseline PSA and age on PSA change over time. RESULTS: • In a model with prostate volume, age and baseline PSA, there was no significant relationship between prostate volume and PSA variability (BLSA, P = 0.57; AS, P = 0.49). • Only baseline PSA showed a significant relationship to PSA yearly variability (PSAYV) (P < 0.001). Specifically, a one unit higher baseline PSA (ng/mL) corresponded on average to 0.09 and 0.06 ng/mL per year higher PSAYV in the BLSA and AS populations, respectively. CONCLUSIONS: • The results of the present study suggest that the primary driver of PSA variability is the baseline PSA level, rather than prostate volume. • Clinicians might consider the baseline PSA level to help predict the expected variability in serial PSA measurements.",
author = "Nichols, {John H.} and Stacy Loeb and E. Metter and Luigi Ferrucci and Carter, {H. Ballentine}",
year = "2012",
month = "5",
day = "1",
doi = "10.1111/j.1464-410X.2011.10663.x",
language = "English (US)",
volume = "109",
pages = "1304--1308",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - The relationship between prostate volume and prostate-specific antigen variability

T2 - Data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program

AU - Nichols, John H.

AU - Loeb, Stacy

AU - Metter, E.

AU - Ferrucci, Luigi

AU - Carter, H. Ballentine

PY - 2012/5/1

Y1 - 2012/5/1

N2 - OBJECTIVE: • To clarify the relationship between serial prostate-specific antigen (PSA) variability and prostate volume in both cancer-free participants from the Baltimore Longitudinal Study of Aging (BLSA) and patients with low-risk prostate cancer from the Johns Hopkins Active Surveillance Program (AS). MATERIALS AND METHODS: • In all, 287 men from the BLSA and 131 patients from the AS were included in the analysis, all with at least two PSA measurements and concurrent prostate volume measurements. • PSA variability was calculated in ng/mL per year, and a linear mixed-effects model was used to determine the relative effects of prostate volume, baseline PSA and age on PSA change over time. RESULTS: • In a model with prostate volume, age and baseline PSA, there was no significant relationship between prostate volume and PSA variability (BLSA, P = 0.57; AS, P = 0.49). • Only baseline PSA showed a significant relationship to PSA yearly variability (PSAYV) (P < 0.001). Specifically, a one unit higher baseline PSA (ng/mL) corresponded on average to 0.09 and 0.06 ng/mL per year higher PSAYV in the BLSA and AS populations, respectively. CONCLUSIONS: • The results of the present study suggest that the primary driver of PSA variability is the baseline PSA level, rather than prostate volume. • Clinicians might consider the baseline PSA level to help predict the expected variability in serial PSA measurements.

AB - OBJECTIVE: • To clarify the relationship between serial prostate-specific antigen (PSA) variability and prostate volume in both cancer-free participants from the Baltimore Longitudinal Study of Aging (BLSA) and patients with low-risk prostate cancer from the Johns Hopkins Active Surveillance Program (AS). MATERIALS AND METHODS: • In all, 287 men from the BLSA and 131 patients from the AS were included in the analysis, all with at least two PSA measurements and concurrent prostate volume measurements. • PSA variability was calculated in ng/mL per year, and a linear mixed-effects model was used to determine the relative effects of prostate volume, baseline PSA and age on PSA change over time. RESULTS: • In a model with prostate volume, age and baseline PSA, there was no significant relationship between prostate volume and PSA variability (BLSA, P = 0.57; AS, P = 0.49). • Only baseline PSA showed a significant relationship to PSA yearly variability (PSAYV) (P < 0.001). Specifically, a one unit higher baseline PSA (ng/mL) corresponded on average to 0.09 and 0.06 ng/mL per year higher PSAYV in the BLSA and AS populations, respectively. CONCLUSIONS: • The results of the present study suggest that the primary driver of PSA variability is the baseline PSA level, rather than prostate volume. • Clinicians might consider the baseline PSA level to help predict the expected variability in serial PSA measurements.

UR - http://www.scopus.com/inward/record.url?scp=84859830101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859830101&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2011.10663.x

DO - 10.1111/j.1464-410X.2011.10663.x

M3 - Article

VL - 109

SP - 1304

EP - 1308

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 9

ER -